Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-09-08
DOI
10.3389/fcell.2021.694363
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-Cell mediated anti-tumor immunity in an esophageal adenocarcinoma model
- (2021) Ali H. Zaidi et al. Oncotarget
- Selinexor for the treatment of multiple myeloma
- (2020) Klaus Podar et al. EXPERT OPINION ON PHARMACOTHERAPY
- Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study
- (2020) L. H. Mammatas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cytochrome P450 2E1 and its roles in disease
- (2020) F. Peter Guengerich CHEMICO-BIOLOGICAL INTERACTIONS
- Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients
- (2020) Warit Ruanglertboon et al. International Journal of Clinical Oncology
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Checkpoint Blockade Therapy in Lymphoma
- (2020) Ayumi Kuzume et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
- (2019) K M Heinhuis et al. ANNALS OF ONCOLOGY
- Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer
- (2019) Jianying Jin et al. PATHOLOGY & ONCOLOGY RESEARCH
- Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer
- (2019) Cora N Sternberg Future Oncology
- Treatment of Advanced Prostate Cancer
- (2019) Min Yuen Teo et al. Annual Review of Medicine
- Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial
- (2019) Arnauld C. Verschuur et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Lenvatinib: A Review in Hepatocellular Carcinoma
- (2019) Zaina T. Al-Salama et al. DRUGS
- Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer
- (2019) Haris Zahoor et al. INVESTIGATIONAL NEW DRUGS
- CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
- (2019) Bogdan Musielak et al. MOLECULES
- An evaluation of fulvestrant for the treatment of metastatic breast cancer
- (2019) Mohsin Soleja et al. EXPERT OPINION ON PHARMACOTHERAPY
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting DNA repair in cancer: current state and novel approaches
- (2019) Apostolos Klinakis et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib
- (2019) Chengzhong Lin et al. CANCER LETTERS
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
- (2019) Brian I Rini et al. LANCET ONCOLOGY
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Small Molecules Drive Big Improvements in Immuno-Oncology Therapies
- (2018) Bayard R. Huck et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway
- (2018) Xinghao Ai et al. BMC CANCER
- Novel Sigma-1 receptor antagonists: from opioids to small molecules: what is new?
- (2018) Emanuela Arena et al. Future Medicinal Chemistry
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Degradation of Androgen Receptor through Small Molecules for Prostate Cancer
- (2018) Raoling Ge et al. CURRENT CANCER DRUG TARGETS
- A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)
- (2018) Shabnam Shaabani et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma
- (2018) Nicole A Carreau et al. Future Oncology
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytochrome P450 epoxygenases and cancer: A genetic and a molecular perspective
- (2018) Lindsay N. Sausville et al. PHARMACOLOGY & THERAPEUTICS
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
- (2017) Kenichi Suda et al. Journal of Thoracic Oncology
- Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
- (2017) J Deng et al. LEUKEMIA
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defective DNA repair mechanisms in prostate cancer: impact of olaparib
- (2017) Francesca De Felice et al. Drug Design Development and Therapy
- Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts
- (2016) Elena Moroz et al. ADVANCED DRUG DELIVERY REVIEWS
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis
- (2016) Tedman Ehlers et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
- (2016) Peng Wu et al. DRUG DISCOVERY TODAY
- Designing small molecule CXCR3 antagonists
- (2016) James E. Pease Expert Opinion on Drug Discovery
- International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007
- (2016) Jessica L. Petrick et al. INTERNATIONAL JOURNAL OF CANCER
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Identification of noreremophilane-based inhibitors of angiogenesis using zebrafish assays
- (2016) Kalai Mangai Muthukumarasamy et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
- (2016) Anitha B. Alex et al. Therapeutic Advances in Medical Oncology
- Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing
- (2015) Jasper E. Neggers et al. CHEMISTRY & BIOLOGY
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel benzoxazines as inhibitors of angiogenesis
- (2014) Sara Al-Rawi et al. INVESTIGATIONAL NEW DRUGS
- The evolution of cancer surgery and future perspectives
- (2014) Lynda Wyld et al. Nature Reviews Clinical Oncology
- Drug Resistance in Cancer: An Overview
- (2014) Genevieve Housman et al. Cancers
- Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP)
- (2013) Danwen Yang et al. Future Oncology
- Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
- (2013) Ying-Qing Wang et al. Marine Drugs
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- (2013) Francesco Lo-Coco et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1
- (2013) Qingxiang Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of B7 family molecules in hematologic malignancy
- (2012) P. Greaves et al. BLOOD
- Retinoids, Retinoic Acid Receptors, and Cancer
- (2011) Xiao-Han Tang et al. Annual Review of Pathology-Mechanisms of Disease
- Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors
- (2011) Shar-yin N Huang et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts
- (2010) Jochen Rössler et al. INTERNATIONAL JOURNAL OF CANCER
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- Androgen deprivation therapy for prostate cancer
- (2008) Eric A Singer et al. EXPERT OPINION ON PHARMACOTHERAPY
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now